PL3728271T3 - Związki makrocykliczne do leczenia chorób - Google Patents

Związki makrocykliczne do leczenia chorób

Info

Publication number
PL3728271T3
PL3728271T3 PL18893293.3T PL18893293T PL3728271T3 PL 3728271 T3 PL3728271 T3 PL 3728271T3 PL 18893293 T PL18893293 T PL 18893293T PL 3728271 T3 PL3728271 T3 PL 3728271T3
Authority
PL
Poland
Prior art keywords
treating diseases
macrocyclic compounds
macrocyclic
compounds
diseases
Prior art date
Application number
PL18893293.3T
Other languages
English (en)
Inventor
Evan W. ROGERS
Jingrong Jean Cui
Dayong Zhai
Han Zhang
Jane Ung
Wei Deng
Jeffrey WHITTEN
Original Assignee
Turning Point Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics, Inc. filed Critical Turning Point Therapeutics, Inc.
Publication of PL3728271T3 publication Critical patent/PL3728271T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18893293.3T 2017-12-19 2018-12-18 Związki makrocykliczne do leczenia chorób PL3728271T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13
PCT/US2018/066158 WO2019126121A1 (en) 2017-12-19 2018-12-18 Macrocyclic compounds for treating disease

Publications (1)

Publication Number Publication Date
PL3728271T3 true PL3728271T3 (pl) 2023-01-23

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18893293.3T PL3728271T3 (pl) 2017-12-19 2018-12-18 Związki makrocykliczne do leczenia chorób

Country Status (29)

Country Link
US (3) US10745416B2 (pl)
EP (2) EP3728271B1 (pl)
JP (2) JP7194188B2 (pl)
KR (1) KR102814342B1 (pl)
CN (1) CN111511746B (pl)
AU (1) AU2018392332B2 (pl)
BR (1) BR112020012319A2 (pl)
CA (1) CA3083674A1 (pl)
CL (1) CL2020001632A1 (pl)
CY (1) CY1125772T1 (pl)
DK (1) DK3728271T3 (pl)
EC (1) ECSP20033467A (pl)
ES (1) ES2929467T3 (pl)
HR (1) HRP20221502T1 (pl)
HU (1) HUE060711T2 (pl)
IL (1) IL275265B2 (pl)
JO (1) JOP20200152A1 (pl)
LT (1) LT3728271T (pl)
MX (1) MX2020006490A (pl)
PE (1) PE20200937A1 (pl)
PH (1) PH12020550901A1 (pl)
PL (1) PL3728271T3 (pl)
PT (1) PT3728271T (pl)
RS (1) RS63787B1 (pl)
SG (1) SG11202005590PA (pl)
SI (1) SI3728271T1 (pl)
SM (1) SMT202200443T1 (pl)
TW (1) TW201930312A (pl)
WO (1) WO2019126121A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
KR20240152947A (ko) 2017-10-18 2024-10-22 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
US20220411439A1 (en) 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
AU2020395136A1 (en) * 2019-12-03 2022-07-07 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態
JP2023528907A (ja) 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー，リミティド 大環状構造を有する化合物及びその使用
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
US20250002505A1 (en) * 2021-10-05 2025-01-02 Turning Point Therapeutics, Inc. Synthesis of macroyclic compounds
CN119630675A (zh) * 2022-07-22 2025-03-14 南京明德新药研发有限公司 含三并环的大环类化合物及其应用
EP4573095A1 (en) * 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
JP7571173B2 (ja) 2023-02-24 2024-10-22 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679053B2 (en) * 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2004526676A (ja) 2000-12-08 2004-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド キナーゼ阻害剤として有用な大員複素環式化合物
US8815872B2 (en) 2008-09-08 2014-08-26 Merck Patent Gmbh Macrocyclics pyrimidines as aurora kinase inhibitors
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
MX2013005445A (es) * 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
US10457691B2 (en) * 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
FI3733187T3 (fi) 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
EP3415518B1 (en) * 2016-03-03 2020-07-08 Shenzhen TargetRx, Inc. Macrocycle and composition comprising thereof
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
KR20240152947A (ko) 2017-10-18 2024-10-22 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126122A1 (en) * 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
WO2019201282A1 (zh) 2018-04-18 2019-10-24 成都先导药物开发股份有限公司 一种大环类激酶抑制剂

Also Published As

Publication number Publication date
WO2019126121A1 (en) 2019-06-27
LT3728271T (lt) 2022-12-12
PH12020550901A1 (en) 2021-05-17
HUE060711T2 (hu) 2023-04-28
EP4151641A1 (en) 2023-03-22
IL275265A (en) 2020-07-30
SMT202200443T1 (it) 2023-01-13
MX2020006490A (es) 2020-08-17
ES2929467T3 (es) 2022-11-29
CA3083674A1 (en) 2019-06-27
PE20200937A1 (es) 2020-09-17
TW201930312A (zh) 2019-08-01
JP7194188B2 (ja) 2022-12-21
AU2018392332B2 (en) 2023-08-03
US20200190110A1 (en) 2020-06-18
US10745416B2 (en) 2020-08-18
IL275265B2 (en) 2023-07-01
CN111511746B (zh) 2024-01-09
EP3728271A4 (en) 2021-06-23
IL275265B1 (en) 2023-03-01
AU2018392332A1 (en) 2020-06-11
DK3728271T3 (da) 2022-12-19
CY1125772T1 (el) 2026-02-25
EP3728271A1 (en) 2020-10-28
SI3728271T1 (sl) 2023-01-31
US20200392160A1 (en) 2020-12-17
JP2021506850A (ja) 2021-02-22
CN111511746A (zh) 2020-08-07
KR20200101358A (ko) 2020-08-27
US11286265B2 (en) 2022-03-29
EP3728271B1 (en) 2022-09-28
KR102814342B1 (ko) 2025-05-29
BR112020012319A2 (pt) 2020-11-24
PT3728271T (pt) 2022-10-06
ECSP20033467A (es) 2020-09-30
JP2023027237A (ja) 2023-03-01
RS63787B1 (sr) 2022-12-30
US20220306652A1 (en) 2022-09-29
SG11202005590PA (en) 2020-07-29
HRP20221502T1 (hr) 2023-03-31
CL2020001632A1 (es) 2020-11-20
JOP20200152A1 (ar) 2022-10-30

Similar Documents

Publication Publication Date Title
LT3728271T (lt) Makrocikliniai junginiai, skirti ligų gydymui
SG11201705093UA (en) Composition for treating il-6-related diseases
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL249229B (en) Compounds for the treatment of brain cancer
HUE050567T2 (hu) Triciklusos heterociklusok rák kezelésére
IL251790B (en) Compounds include thiazole for the treatment of culture diseases
GB201709402D0 (en) Compounds for treating t-pll
GB201716942D0 (en) Therapeutic compounds
IL259297A (en) Heterocyclic compounds for the treatment of disease
ZA201906047B (en) Compounds for treating tuberculosis
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
ZA201704589B (en) Compounds for the treatment of cancer
EP3261635A4 (en) Compounds for treating ocular diseases
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
HK40036156A (en) Macrocyclic compounds for treating disease
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201715210D0 (en) Macrocyclic compounds
GB201712390D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712394D0 (en) Therapeutic compounds
GB201712395D0 (en) Therapeutic compounds
EP3354271A4 (en) Agent for treating arthrological diseases